Published in Pharma Law Weekly, September 12th, 2006
2ME2 is currently in Phase 1 and 2 clinical trials for cancer (Panzem NCD), as well as in preclinical development for rheumatoid arthritis. This patent further strengthens EntreMed's intellectual property protection for 2ME2 to include highly purified compositions and extends the patent life for 2ME2 to 2022.
Patent No. 7,087,592 entitled "Compositions Comprising Purified 2-Methoxyestradiol...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.